Characterizing the molecular mechanisms of acquired temozolomide resistance in the U251 glioblastoma cell line by protein microarray

Lin,Jing; Zuo,Jianling; Cui,Yong; Song,Chaoli; Wu,Xiaojun; Feng,Huaizhi; Li,Jian; Li,Shuo; Xu,Qinian; Wei,Wenxin; Qiu,Guanzhong; He,Hua

doi:10.3892/or.2018.6322

Characterizing the molecular mechanisms of acquired temozolomide resistance in the U251 glioblastoma cell line by protein microarray

Authors:
- Jing Lin
- Jianling Zuo
- Yong Cui
- Chaoli Song
- Xiaojun Wu
- Huaizhi Feng
- Jian Li
- Shuo Li
- Qinian Xu
- Wenxin Wei
- Guanzhong Qiu
- Hua He
View Affiliations

Affiliations: Department of Neurosurgery, The 452 Hospital of Western Air Force, Chengdu, Sichuan 610021, P.R. China, The Brain Research Laboratory of The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, P.R. China, Department of Neurosurgery, The 411 Hospital of the People's Liberation Army, Shanghai 200081, P.R. China, Department of Neurosurgery, Changzheng Hospital, The Second Military Medical University, Shanghai 200003, P.R. China, Department of Nutrition, The 452 Hospital of Western Air Force, Chengdu, Sichuan 610021, P.R. China, Department of Urology, The 452 Hospital of Western Air Force, Chengdu, Sichuan 610021, P.R. China, The Eastern Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai 200438, P.R. China, Department of Neurosurgery, General Hospital of Jinan Military Command, Jinan, Shandong 250031, P.R. China
Published online on: March 19, 2018 https://doi.org/10.3892/or.2018.6322
Pages: 2333-2341

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Acquired chemoresistance refers to tumor cells gradually losing their sensitivity to anticancer drugs during the course of treatment, resulting in tumor progression or recurrence. This phenomenon, which has deleterious outcomes for the patient, has long been observed in patients with glioblastoma receiving temozolomide (TMZ)-based radiochemotherapy. Currently, the mechanisms for acquired TMZ chemoresistance are not fully understood. In the present study, a TMZ-resistant cell line U251R with a 4-fold 50% inhibition concentration compared with its TMZ-sensitive parent cell line was isolated by incremental long-time TMZ treatment in the human glioblastoma cell line U251. Fluorescence-activated cell sorting analysis indicated G2/M arrest and a lower proportion of cells in the S phase, accompanied by a decreased apoptosis rate in the U251R cell line compared with the parental U251 cell line. In addition, a sphere-formation assay indicated an increased self-renewal capacity in U251R cells. Furthermore, a high-throughput protein microarray unveiled more than 200 differentially expressed proteins as potential molecular targets accounting for acquired TMZ resistance. Subsequent bioinformatics analysis illustrated the molecular and signaling networks and revealed the central role of SRC. Immunoblotting and reverse-transcription quantitative polymerase chain reaction analysis further confirmed the expressional upregulation of SRC family kinases. Moreover, SRC knockdown led to partial reversal of TMZ resistance in the U251R cell line and sensitization in the U373 cell line. These data helped to develop a comprehensive understanding of survival strategies, particularly with respect to pro-stemness regulation, which could be potential targets for overcoming TMZ resistance.

View Figures

View References

1	Bleeker FE, Molenaar RJ and Leenstra S: Recent advances in the molecular understanding of glioblastoma. J Neurooncol. 108:11–27. 2012. View Article : Google Scholar : PubMed/NCBI
2	Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY and Olson JJ: Exciting new advances in neuro-oncology: The avenue to a cure for malignant glioma. CA Cancer J Clin. 60:166–193. 2010. View Article : Google Scholar : PubMed/NCBI
3	Newlands ES, O'Reilly SM, Glaser MG, Bower M, Evans H, Brock C, Brampton MH, Colquhoun I, Lewis P, Rice-Edwards JM, et al: The Charing Cross Hospital experience with temozolomide in patients with gliomas. Eur J Cancer. 32A:2236–2241. 1996. View Article : Google Scholar : PubMed/NCBI
4	Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al: European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
5	Zhang J, Stevens MF, Laughton CA, Madhusudan S and Bradshaw TD: Acquired resistance to temozolomide in glioma cell lines: Molecular mechanisms and potential translational applications. Oncology. 78:103–114. 2010. View Article : Google Scholar : PubMed/NCBI
6	D'Atri S, Tentori L, Lacal PM, Graziani G, Pagani E, Benincasa E, Zambruno G, Bonmassar E and Jiricny J: Involvement of the mismatch repair system in temozolomide-induced apoptosis. Mol Pharmacol. 54:334–341. 1998. View Article : Google Scholar : PubMed/NCBI
7	Lu C and Shervington A: Chemoresistance in gliomas. Mol Cell Biochem. 312:71–80. 2008. View Article : Google Scholar : PubMed/NCBI
8	Hall DA, Ptacek J and Snyder M: Protein microarray technology. Mech Ageing Dev. 128:161–167. 2007. View Article : Google Scholar : PubMed/NCBI
9	Sørensen MD, Fosmark S, Hellwege S, Beier D, Kristensen BW and Beier CP: Chemoresistance and chemotherapy targeting stem-like cells in malignant glioma. Adv Exp Med Biol. 853:111–138. 2015. View Article : Google Scholar : PubMed/NCBI
10	Izumiya M, Kabashima A, Higuchi H, Igarashi T, Sakai G, Iizuka H, Nakamura S, Adachi M, Hamamoto Y, Funakoshi S, et al: Chemoresistance is associated with cancer stem cell-like properties and epithelial-to-mesenchymal transition in pancreatic cancer cells. Anticancer Res. 32:3847–3853. 2012.PubMed/NCBI
11	von Manstein V, Yang CM, Richter D, Delis N, Vafaizadeh V and Groner B: Resistance of cancer cells to targeted therapies through the activation of compensating signaling loops. Curr Signal Transduct Ther. 8:193–202. 2013. View Article : Google Scholar : PubMed/NCBI
12	Spiegl-Kreinecker S, Buchroithner J, Elbling L, Steiner E, Wurm G, Bodenteich A, Fischer J, Micksche M and Berger W: Expression and functional activity of the ABC-transporter proteins P-glycoprotein and multidrug-resistance protein 1 in human brain tumor cells and astrocytes. J Neurooncol. 57:27–36. 2002. View Article : Google Scholar : PubMed/NCBI
13	Cui Y, Lin J, Zuo J, Zhang L, Dong Y, Hu G, Luo C, Chen J and Lu Y: AKT2-knockdown suppressed viability with enhanced apoptosis, and attenuated chemoresistance to temozolomide of human glioblastoma cells in vitro and in vivo. Onco Targets Ther. 8:1681–1690. 2015.PubMed/NCBI
14	Zhang J, Stevens MF and Bradshaw TD: Temozolomide: Mechanisms of action, repair and resistance. Curr Mol Pharmacol. 5:102–114. 2012. View Article : Google Scholar : PubMed/NCBI
15	Bobola MS, Kolstoe DD, Blank A, Chamberlain MC and Silber JR: Repair of 3-methyladenine and abasic sites by base excision repair mediates glioblastoma resistance to temozolomide. Front Oncol. 2:1762012. View Article : Google Scholar : PubMed/NCBI
16	Fu D, Calvo JA and Samson LD: Balancing repair and tolerance of DNA damage caused by alkylating agents. Nat Rev Cancer. 12:104–120. 2012. View Article : Google Scholar : PubMed/NCBI
17	Happold C, Roth P, Wick W, Schmidt N, Florea AM, Silginer M, Reifenberger G and Weller M: Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells. J Neurochem. 122:444–455. 2012. View Article : Google Scholar : PubMed/NCBI
18	Wertz IE, Kusam S, Lam C, Okamoto T, Sandoval W, Anderson DJ, Helgason E, Ernst JA, Eby M, Liu J, et al: Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature. 471:110–114. 2011. View Article : Google Scholar : PubMed/NCBI
19	Kanzawa T, Germano IM, Komata T, Ito H, Kondo Y and Kondo S: Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ. 11:448–457. 2004. View Article : Google Scholar : PubMed/NCBI
20	Lin C-J, Lee C-C, Shih YL, Lin CH, Wang SH, Chen TH and Shih CM: Inhibition of mitochondria- and endoplasmic reticulum stress-mediated autophagy augments temozolomide-induced apoptosis in glioma cells. PLoS One. 7:e387062012. View Article : Google Scholar : PubMed/NCBI
21	Kogias E, Osterberg N, Baumer B, Psarras N, Koentges C, Papazoglou A, Saavedra JE, Keefer LK and Weyerbrock A: Growth-inhibitory and chemosensitizing effects of the glutathione-S-transferase-π-activated nitric oxide donor PABA/NO in malignant gliomas. Int J Cancer. 130:1184–1194. 2012. View Article : Google Scholar : PubMed/NCBI
22	Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, Lu L, Irvin D, Black KL and Yu JS: Analysis of gene expression and chemoresistance of CD133⁺ cancer stem cells in glioblastoma. Mol Cancer. 5:672006. View Article : Google Scholar : PubMed/NCBI
23	Takuro H, Kazuhide A and Yuichi H: The Cdk inhibitor flavopiridol enhances temozolomide-induced cytotoxicity in human glioma cells. J Neurooncol. 115:169–178. 2013. View Article : Google Scholar : PubMed/NCBI
24	Hirose Y, Katayama M, Mirzoeva OK, Berger MS and Pieper RO: Akt activation suppresses Chk2-mediated, methylating agent-induced G2 arrest and protects from temozolomide-induced mitotic catastrophe and cellular senescence. Cancer Res. 65:4861–4869. 2005. View Article : Google Scholar : PubMed/NCBI
25	Ye F, Zhang Y, Liu Y, Yamada K, Tso JL, Menjivar JC, Tian JY, Yong WH, Schaue D, Mischel PS, et al: Protective properties of radio-chemoresistant glioblastoma stem cell clones are associated with metabolic adaptation to reduced glucose dependence. PLoS One. 8:e803972013. View Article : Google Scholar : PubMed/NCBI
26	Chen Y-S, Wu M-J, Huang C-Y, Lin SC, Chuang TH, Yu CC and Lo JF: CD133/Src axis mediates tumor initiating property and epithelial-mesenchymal transition of head and neck cancer. PLoS One. 6:e280532011. View Article : Google Scholar : PubMed/NCBI
27	Liu X, Madhankumar AB, Slagle-Webb B, Sheehan JM, Surguladze N and Connor JR: Heavy chain ferritin siRNA delivered by cationic liposomes increases sensitivity of cancer cells to chemotherapeutic agents. Cancer Res. 71:2240–2249. 2011. View Article : Google Scholar : PubMed/NCBI
28	Isvoran A, Louet M, Vladoiu DL, Craciun D, Loriot MA, Villoutreix BO and Miteva MA: Pharmacogenomics of the cytochrome P450 2C family: Impacts of amino acid variations on drug metabolism. Drug Discov Today. 22:366–376. 2017. View Article : Google Scholar : PubMed/NCBI
29	Pacaud R, Cheray M, Nadaradjane A, Vallette FM and Cartron PF: Histone H3 phosphorylation in GBM: A new rational to guide the use of kinase inhibitors in anti-GBM therapy. Theranostics. 5:12–22. 2015. View Article : Google Scholar : PubMed/NCBI
30	Borges KS, Castro-Gamero AM, Moreno DA, da Silva Silveira V, Brassesco MS, de Paula Queiroz RG, de Oliveira HF, Carlotti CG Jr, Scrideli CA and Tone LG: Inhibition of Aurora kinases enhances chemosensitivity to temozolomide and causes radiosensitization in glioblastoma cells. J Cancer Res Clin Oncol. 138:405–414. 2012. View Article : Google Scholar : PubMed/NCBI
31	Tentori L, Ricci-Vitiani L, Muzi A, Ciccarone F, Pelacchi F, Calabrese R, Runci D, Pallini R, Caiafa P and Graziani G: Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide. BMC Cancer. 14:1512014. View Article : Google Scholar : PubMed/NCBI
32	Tang TK, Chiu SC, Lin CW, Su MJ and Liao MH: Induction of survivin inhibition, G2/M cell cycle arrest and autophagic on cell death in human malignant glioblastoma cells. Chin J Physiol. 58:95–103. 2015.PubMed/NCBI
33	Zhao Z, Liu Y, He H, Chen X, Chen J and Lu YC: Candidate genes influencing sensitivity and resistance of human glioblastoma to Semustine. Brain Res Bull. 86:189–194. 2011. View Article : Google Scholar : PubMed/NCBI
34	Eich M, Roos WP, Nikolova T and Kaina B: Contribution of ATM and ATR to the resistance of glioblastoma and malignant melanoma cells to the methylating anticancer drug temozolomide. Mol Cancer Ther. 12:2529–2540. 2013. View Article : Google Scholar : PubMed/NCBI
35	Munoz JL, Rodriguez-Cruz V, Greco SJ, Nagula V, Scotto KW and Rameshwar P: Temozolomide induces the production of epidermal growth factor to regulate MDR1 expression in glioblastoma cells. Mol Cancer Ther. 13:2399–2411. 2014. View Article : Google Scholar : PubMed/NCBI
36	Popescu AM, Alexandru O, Brindusa C, Purcaru SO, Tache DE, Tataranu LG, Taisescu C and Dricu A: Targeting the VEGF and PDGF signaling pathway in glioblastoma treatment. Int J Clin Exp Pathol. 8:7825–7837. 2015.PubMed/NCBI
37	Auger N, Thillet J, Wanherdrick K, Idbaih A, Legrier ME, Dutrillaux B, Sanson M and Poupon MF: Genetic alterations associated with acquired temozolomide resistance in SNB-19, a human glioma cell line. Mol Cancer Ther. 5:2182–2192. 2006. View Article : Google Scholar : PubMed/NCBI
38	Han X, Zhang W, Yang X, Wheeler CG, Langford CP, Wu L, Filippova N, Friedman GK, Ding Q, Fathallah-Shaykh HM, et al: The role of Src family kinases in growth and migration of glioma stem cells. Int J Oncol. 45:302–310. 2014. View Article : Google Scholar : PubMed/NCBI
39	Choi YL, Bocanegra M, Kwon MJ, Shin YK, Nam SJ, Yang JH, Kao J, Godwin AK and Pollack JR: LYN is a mediator of epithelial-mesenchymal transition and a target of dasatinib in breast cancer. Cancer Res. 70:2296–2306. 2010. View Article : Google Scholar : PubMed/NCBI
40	Boivin D, Labbé D, Fontaine N, Lamy S, Beaulieu E, Gingras D and Béliveau R: The stem cell marker CD133 (prominin-1) is phosphorylated on cytoplasmic tyrosine-828 and tyrosine-852 by Src and Fyn tyrosine kinases. Biochemistry. 48:3998–4007. 2009. View Article : Google Scholar : PubMed/NCBI
41	Li XY, Jiang LJ, Chen L, Ding ML, Guo HZ, Zhang W, Zhang HX, Ma XD, Liu XZ, Xi XD, et al: RIG-I modulates Src-mediated AKT activation to restrain leukemic stemness. Mol Cell. 53:407–419. 2014. View Article : Google Scholar : PubMed/NCBI